



## PRESS RELEASE

### LXRepair receives €750,000 in funding from BPI France as part of the DeepTech program

- BPI France's DeepTech program aims to help finance disruptive innovation projects before their industrial and commercial launch.
- LXRepair will receive €750,000 to launch as soon as 2024 the first predictive test of radiotherapy treatment toxicity for patients suffering from breast or prostate cancer

**Grenoble, July 8th, 2021 - LXRepair**, a biotechnology start-up specializing in personalized medicine testing, today announces the granting of €750,000 in funding under the BPI France DeepTech program. This program supports advanced and highly differentiating biotechnology projects with significant commercial potential.

This is the case of LXRepair: predicting serious late side effects is the "Holy Grail" of radiotherapists. Caused by DNA repair defects, they affect 5 to 30% of patients and cost around 600 million euros per year in Europe and the United States for breast and prostate cancers alone.

*"I am very pleased with this announcement. LXRepair has clinically demonstrated the benefits of its breakthrough technology for a critical indication. This funding will allow us to confirm the already identified and patented biomarkers through a new clinical study, but also to develop an in vitro diagnostic medical device based on a blood sample, up to the CE marking planned for 2023 "*, said **Sylvie Sauvaigo, President, Founder and CSO of LXRepair**.

**Stéphane Altaba, CEO of LXRepair**, added: *"the DeepTech program helps companies conducting experimental development work to develop innovative products with concrete commercialization perspectives. We are therefore very proud to receive this funding. But above all, we are convinced that we will soon be able to personalize the management of more than one million cancer patients at risk of developing serious and disabling side effects from radiotherapy, thanks to this first breakthrough functional test. This is an exciting perspective, which explains the trust that BPI France has placed in us today"*.

### ABOUT LXREPAIR

LXRepair is a biotechnology company whose ambition is to provide all cancer patients with access to the best possible treatment.

Its first product, Safer RAD-LX®, a diagnostic test using LXRepair proprietary technology for analyzing an individual's DNA repair capacity is expected to be launched as early as 2024.

This assay will predict, the late severe toxicity occurring in patient undergoing radiotherapy treatment for prostate or breast cancer

This simple, rapid and accurate blood test, is part of a series of assays that the company will launch in the coming years and that will bring about a lasting change in the approach to oncology care ; it will prevent the patient's suffering and high costs associated with the administration of treatment that is inappropriate in terms of efficacy or toxicity.

Today more than 9 million patients are treated worldwide every year with radiotherapy. Approximately 10% of these patients develop late severe side effects that are often disabling and always leading to a degradation of their quality of life.

#### Contact:

Sylvie Sauvaigo: +33. 6.21.21.77.95. [sylvie.sauvaigo@lxrepair.com](mailto:sylvie.sauvaigo@lxrepair.com)

Stéphane Altaba : +33.6.72.87.20.03. [stephane.altaba@lxrepair.com](mailto:stephane.altaba@lxrepair.com)

#### Media Relations:

Jean-Baptiste Mounier: +33.7.67.47.42.91. [jean-baptiste.mounier@lxrepair.com](mailto:jean-baptiste.mounier@lxrepair.com)